

Amendments to the Claims:

Please kindly amend the claims as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-45 (canceled)

46. (Currently amended) A method of preventing and/or treating a disease associated with a disease associated molecule (DAM), said method comprising administering an ScFv antibody (ScFv Ab) capable of recognizing ~~[a-ox]~~ the DAM.

47. (Original) The method of claim 46 wherein the DAM is a tumor associated antigen (TAA).

48. (Original) The method according to claim 46 or claim 47 wherein the ScFv Ab has the sequence presented as SEQ ID No 1 or SEQ ID No 2.

49. (Original) The method according to claim 46 or claim 47 wherein the ScFv Ab has the sequence presented as SEQ ID No 3.

50. (Original) The method according to claim 46 or claim 47 wherein the ScFv Ab has the sequence presented as SEQ ID No 4.

51. (Currently amended) A nucleotide sequence encoding the ScFv Ab ~~according of~~ claim 46 or claim 47.

52. (Original) An isolated nucleic acid molecule encoding an ScFv antibody (ScFv Ab) having a sequence set forth in SEQ ID Nos. 1, 2, 3 or 4 or a variant, homologue, fragment or derivative thereof.

53. (Original) The isolated nucleic acid molecule of claim 52 having a sequence set forth in SEQ ID Nos. 1, 2, 3, or 4.

54. (Original) An isolated nucleic acid molecule having the nucleotide sequence presented as SEQ ID No 5 or SEQ ID No 6 or a variant, homologue, fragment or derivative thereof.

55. (Original) An isolated nucleic acid molecule having the nucleotide sequence presented as SEQ ID No 7 or a variant, homologue, fragment or derivative thereof.

56. (Original) An isolated nucleic acid molecule having the nucleotide sequence presented as SEQ ID No 8 or a variant, homologue, fragment or derivative thereof.

57. (Original) An isolated nucleic acid molecule having the nucleotide sequence presented as SEQ ID No 5 or SEQ ID No 6.

58. (Original) An isolated nucleic acid molecule having the nucleotide sequence presented as SEQ ID No 7.

59. (Original) An isolated nucleic acid molecule having the nucleotide sequence presented as SEQ ID No 8.

60. (Original) A nucleotide sequence capable of hybridising to the nucleotide sequence according to any one of claims 54-59 or a sequence that is complementary to the hybridisable nucleotide sequence.

61. (Original) A nucleotide sequence according to any one of claims 54-59 wherein the nucleotide sequence is operably linked to a promoter.

62. (Original) A nucleotide sequence according to claim 60 wherein the nucleotide sequence is operably linked to a promoter.

63. (Currently amended) A construct, vector, plasmid, or host cell comprising the nucleotide sequence according to any one of claims 54-59.

64. (Currently amended) A construct, vector, plasmid, or host cell comprising the nucleotide sequence according to claim 60.

65. (Currently amended) A construct, vector, plasmid, or host cell comprising the nucleotide sequence according to claim 61.

66. (Original) A process for preparing an ScFv antibody (ScFv Ab) capable of recognizing a disease associated molecule comprising expressing a nucleic acid molecule of any one of claims 54-59 and optionally isolating and/or purifying the ScFv Ab.

67. (Original) A process for preparing an ScFv antibody (ScFv Ab) wherein DAM is TAA.

68. (Currently amended) A process for preparing an ScFv antibody (~~ScFv Ab~~) (ScFv Ab) wherein ScFv Ab has a sequence as presented in SEQ ID Nos 1, 2, 3, or 4.

69. (Original) A ScFv Ab produced by the process according to claim 66.

70. (Currently amended) An *in vitro* method for obtaining a ScFv Ab according to claim 69 comprising:

(i) preparing a phage library wherein each phage comprises a nucleic acid construct encoding a protein comprising a potential binding domain;

(ii) causing the expression of said potential proteins and the display of the potential binding domains on the outer surface of the phage;

~~(v)~~(iii) contacting the phage library with a DAM target under conditions such that the potential binding domains and the DAM target interact;

~~(v)~~(iv) separating the phage displaying a domain that binds the DAM target from phage that do not bind;

- (v) recovering at least one phage displaying on its outer surface a protein which binds the DAM target;
- (vi) amplifying the binding protein *in vitro* to create a second enriched library of binding structures;
- (vii) repeating steps (iii) to (vi) at least twice;
- (viii) expressing the nucleic acid encoding the binding protein under *in vitro* conditions;
- and
- (ix) determining whether the binding protein interacts with the DAM by detecting the presence or absence of a signal.

71. (Original) An *in vitro* method according to claim 70 wherein the *in vitro* method is to screen for a ScFv Ab useful in the treatment of a disease.

72. (Original) A process comprising the steps of:
- (a) performing the *in vitro* method according to claim 70 or claim 71;
 - (b) identifying one or more ScFv Abs capable of recognising a DAM by means of a detectable signal; and
 - (c) preparing a quantity of those one or more ScFv Abs.

73. (Currently amended) A process comprising the steps of:
- (a) performing the method according to claim 70 or claim 71;
 - (b) identifying one or more ScFv Abs capable of recognising a DAM by means of a detectable signal; and
 - (c) preparing a pharmaceutical composition comprising those one or more identified ScFv Abs.

74. (Original) A process comprising the steps of:
- (a) performing the method according to claim 70 or claim 71;
 - (b) identifying one or more ScFv Abs capable of recognising a DAM;

- (c) modifying those one or more identified ScFv Abs capable of recognising a DAM;
and
- (d) preparing a pharmaceutical composition comprising those one or more modified ScFv Abs.

75. (Currently amended) A ScFv antibody (ScFv Ab) ~~capable~~ capable of recognizing a TAA identified by the method of claim 70 or claim 71.

76. (Original) A ScFv Ab according to claim 75 wherein the ScFv Ab is capable of recognising a 5T4 antigen.

77. (Original) An antibody having the binding specificity of an scFv according to claim 75 conjugated to any one or more of an isotope, an enzyme, a carrier protein, a cytotoxic drug, a fluorescent molecule and a radioactive nucleotide.

78. (Currently amended) A method of affecting a disease *in vivo* with an ScFv Ab; wherein the ScFv Ab recognises a DAM antigen in an *in vitro* method; and wherein the *in vitro* method is the method defined in claim 70 or claim 71.

79. (Original) A pharmaceutical composition comprising the ScFv Ab of claim 69.

80. (Original) The pharmaceutical composition of claim 79 further comprising another therapeutic agent.

81. (Original) The pharmaceutical composition of claim 80 wherein the other therapeutically useful agent is a pro-drug activating enzyme.

82. (Original) The pharmaceutical composition of claim 81 wherein the other therapeutically useful agent is a toxin.

83. (Original) A pharmaceutical composition according to claim 79 or claim 80 or claim 81 or claim 82 wherein the ScFv Ab is capable of recognising a 5T4 antigen.

84. (Original) The method of claim 46 further comprising administering a pro-drug activating enzyme or toxin.

85. (Original) A method for *in vivo* imaging and/or adjuvant treatment of a disease associated with a disease associated molecule (DAM) comprising administering an ScFv antibody (ScFv Ab).

86. (Original) The method according to claim 85 wherein the disease is cancer.

87. (Original) A method for screening for agents that modulate a disease associated molecule (DAM) by contacting a DAM with an ScFv Ab as claimed in 69.

88. (Currently amended) A process for diagnosing a disease condition relating to the expression and/or activity of ~~adisease~~ a disease associated molecule (DAM) in an individual comprising:

(i) providing a nucleotide sequence encoding a ScFv Ab as defined in claims 52-56 or an expression product thereof; and

(ii) analysing for the binding of the ScFv Ab to a DAM in a sample derived from the individual;

wherein the binding is indicative of the presence of the DAM in the individual.

89. (Original) A method for inducing a therapeutic response in a mammal with a disease condition associated with a disease associated molecule (DAM) *in vivo* which comprises inoculating the mammal with a ScFv Ab as claimed in claim 69.

90. (Original) A method according to claim 89 wherein the disease condition is a cancer.

91. (Original) A pharmaceutical comprising an ScFv.

92. (Original) An isolated canine 5T4 polypeptide having the amino acid sequence shown in SEQ ID No 14.

93. (Original) An isolated nucleotide sequence capable of encoding a canine 5T4 polypeptide according to claim 92.

94. (Original) An isolated nucleotide sequence according to claim 43, having the sequence shown as SEQ ID NO I5.

95. (Original) An isolated antibody capable of binding specifically to a canine 5T4 polypeptide according to claim 92.